Novolizer (Formoterol Fumarate Dihydrate)

Formoterol selectively stimulates β2‑adrenergic receptors on airway smooth‑muscle cells. This activation increases cyclic AMP, which relaxes the smooth muscle and produces prolonged bronchodilation. The high intrinsic efficacy of formoterol also provides a rapid onset of action, making it suitable for both symptom control and long‑term maintenance therapy.

The prescribed dose of Novolizer is determined by the treating physician based on the patient’s disease severity, age, and response to therapy. Typical regimens involve one or two inhalations twice daily, but exact dosing and frequency must be individualized and documented in the patient’s prescription.

Formoterol is classified as a pregnancy category C medication, meaning it should only be used if the potential benefit justifies the potential risk to the fetus. Limited data are available for breastfeeding; the drug does pass into breast milk in small amounts, so a risk‑benefit assessment by the healthcare provider is essential.

To request Novolizer, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Novolizer delivers formoterol, a LABA with a rapid onset (within minutes) and a long duration (up to 12 hours). Compared with other LABAs such as salmeterol, formoterol provides quicker symptom relief while maintaining similar maintenance efficacy. It is typically used in combination with inhaled corticosteroids, whereas short‑acting bronchodilators are reserved for rescue therapy.

Novolizer should be stored at room temperature below 25 °C. Keep the device in its original packaging, protect it from moisture and direct sunlight, and avoid exposing it to extreme temperatures. Do not attempt to disassemble the inhaler; follow the manufacturer’s instructions for loading and cleaning.

Novolizer is a dry‑powder inhaler. The patient removes the cap, loads a dose by pressing the dose‑release button, inhales forcefully and deeply through the mouthpiece, and then holds the breath for a few seconds. The device is designed for easy dose counting and should be used exactly as instructed by the prescriber.

Serious adverse events include paradoxical bronchospasm (a sudden worsening of breathing), severe cardiac arrhythmias, marked hypokalemia, and anaphylactic reactions. Patients should seek immediate medical attention if they experience sudden breathlessness, chest pain, rapid heartbeat, muscle weakness, or signs of an allergic reaction such as swelling or rash.

Novolizer is contraindicated in patients with a known hypersensitivity to formoterol or any component of the inhaler. It should also be avoided in individuals who have experienced a severe paradoxical bronchospasm with a β2‑agonist. Caution is advised for patients with uncontrolled cardiovascular disease, severe arrhythmias, or those taking non‑selective β‑blockers.